Interferences. Each party will give the other party written notice promptly upon the declaration of any interference involving any of the Patent Rights. In cases where the University controls prosecution and maintenance of the Patent Rights, University will have the sole and exclusive right to determine whether and in what manner to proceed in such interference. In cases where Licensee controls prosecution and maintenance of the Patent Rights, Licensee will have the sole and exclusive right to determine whether and in what manner to proceed in such interference. If the party controlling prosecution and maintenance of the Patent Rights fails to contest the interference, such party will promptly notify the other party. Such other party agrees that it will not (and in the case where Licensee is such other party, will not permit any Sublicensee to), directly or indirectly initiate, support, or without the express written consent of the controlling party participate in, any interference involving any of the Patent Rights.
Interferences. Pseudothrombocytopenia, though infrequent, can result from EDTA-dependent platelet agglutination. Pseudothrombocytopenia may be suspected with the Plateletworks assay if the platelet count determined using the agonist tube is higher than the platelet count determined using the baseline tube (containing EDTA anticoagulant). If pseudothrombocytopenia is suspected, common laboratory practice is to re-draw the blood sample into a sodium citrate collection tube and perform the blood count; the results should be corrected by a factor of 1.1 to account for the sample dilution that occurs with the use of sodium citrate as an anticoagulant. This procedure should be followed using the sodium citrate tube in lieu of the Plateletworks baseline tube, followed by the Plateletworks agonist tube, to determine percent platelet aggregation. • Cell counters utilizing electronic impedance cell counting principles may be subject to known interfering substances which can impact platelet count results. These include: • Microcytes, schizocytes, and WBC fragments, which may interfere with the proper counting of platelets and cause elevated platelet counts. • Agglutinated erythrocytes, which may trap platelets and cause an erroneously low platelet count. • Giant platelets, which may cause an erroneously low platelet count since they may exceed the upper limit threshold for the platelet parameter. • Chemotherapy, which may increase the fragility of platelets and cause low platelet counts • Hemolysis, which contains red cell stroma and may elevate platelet counts. • Acid-citrate-dextrose (ACD) blood, which may contain platelet aggregates that could depress the platelet count. • RBC inclusions, which may produce a spuriously increased platelet count. • Platelet agglutination, due to poor collection techniques or EDTA activation, which may cause a decreased platelet count. Correlation of the Plateletworks assay to platelet aggregometry on platelet rich plasma (PRP) is supported by data generated by testing male and female adults, greater than 18 years of age, at three clinical sites. This includes normal, healthy volunteers, and patients and volunteers who were taking aspirin. All blood samples were acquired from in-dwelling lines or venipuncture using established methods. For the Plateletworks assays and PRP aggregometry, the manufacturers’ recommendations were adhered to as per instructions provided in the package insert. A positive result was equal to or greater than 60% aggregation...
Interferences. With respect to Aradigm Patent Rights and Aradigm New IPR that are licensed to Novo Nordisk under Article 3, in the event that any of such Aradigm Patent Rights, Aradigm Selected Pulmonary Delivery Patent Rights or Aradigm New IPR are subject to an interference action in the United States Patent and Trademark Office, Aradigm shall provide Novo Nordisk with copies of all communications relating to the interference action and shall keep Novo Nordisk reasonably informed of the progress of the interference action. Furthermore, Aradigm shall not enter into any settlement agreement or take other dispositive action in the interference without giving good faith consideration to Novo Nordisk’s interests and concerns, and if such action would have a material adverse impact on Novo Nordisk’s activities in the Field, without obtaining the prior consent of Novo Nordisk (which consent shall not be unreasonably withheld or delayed).
Interferences. If Jazz decides to provoke or institute an interference action with respect to any Third Party Patent Right in the Territory on the basis of any Jazz Patent Right or Codiak Product-Specific Collaboration Patent Right, then Jazz will control such action and be responsible for all of the costs and expenses the Parties incur in performing activities at Jazz’s request in connection with such action. If Codiak decides to provoke or institute an interference action with respect to any Third Party Patent Right in the Territory on the basis of any Codiak Platform Patent Right, then Codiak will control such action and be responsible for all of the costs and expenses the Parties incur in performing activities at Codiak’s request in connection with such action. If the then-prosecuting Party decides to provoke or institute an interference action with respect to any Third Party Patent Right in the Territory on the basis of any Codiak Other Collaboration Patent Right or Joint Collaboration Patent Right, then the then-prosecuting Party will control such action and be responsible for all of the costs and expenses the Parties incur in performing activities at such then-prosecuting Party’s request in connection with such action.
Interferences. The Parties shall each, in good faith, use its respective Commercially Reasonable Efforts to resolve any patent interferences between any of the Parties relating to Patents directed to any Factor or Additional Factor.
Interferences. The two most common interferences in surface water collection include cross contamination and improper collection technique.
Interferences. University will give Licensee written notice promptly upon the declaration of any interference involving any of the Patent Rights. University will have the sole and exclusive right to determine whether and in what manner to proceed with respect to such interference. If University fails to contest the interference. University will promptly notify Licensee. Licensee will not, and will not permit any Sublicensee to, directly or indirectly, initiate, support, participate in, any interference involving any of the Patent Rights.
Interferences. The Parties shall each, in good faith, use its respective Commercially Reasonable Efforts to resolve any patent interferences between any of the Parties relating to Patents directed to GDF-8 or any GDF-8 Licensed Product.
Interferences. (****)1 1 Two paragraphs of confidential information was redacted. CDI Stem Cell License 00-00000 (2) XXXX Agreement #: 11-00206 F. Milestone Fees. Licensee and each sublicensee shall pay to XXXX the amounts detailed below within thirty (30) days of the achievement of the corresponding milestones for each Therapeutic Product in the X-0, X-0 and B-4 Licensed Fields. Milestone Milestone Fee Milestone described in Section 3D(i)(a) of this Agreement $(****) Milestone described in Section 3D(i)(b) of this Agreement $(****) Milestone described in Section 3D(i)(c) of this Agreement $(****) Milestone described in Section 3D(i)(d) of this Agreement $(****) Milestone described in Section 3D(i)(e) of this Agreement $(****) Milestone described in Section 3D(i)(f) of this Agreement $(****)
Interferences. Licensee will give CARDIFF prompt written notice upon the declaration of any interference involving the Licensed Patents. The Parties shall cooperate in the interference proceeding using counsel acceptable to both parties unless there is a Sublicense, in which case the counsel shall be chosen by the Sublicensee. In the absence of a Sublicense, fees and costs incurred in connection with the interference shall be deemed to be Patent Expenses and shall be reimbursed as provided herein. Licensee may terminate its obligation to reimburse for interference expenses upon ninety (90) days written notice, and the claims or patent at issue shall be removed from the Licensed Patents in the United States.
